Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment
Fabry disease (FD, OMIM#301500) is a rare inborn error of the lysosomal enzyme α-galactosidase (α-Gal A, EC 3.2.1.22) and results in progressive substrate accumulation in tissues with a wide range of clinical presentations. Despite the X-linked inheritance, heterozygous females may also be affected....
Main Authors: | Katarina Jurickova, Petra Jungova, Robert Petrovic, Slavomira Mattosova, Tereza Hlavata, Ludmila Kostalova, Anna Hlavata |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/12/6/922 |
Similar Items
-
<i>GLA</i> Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease
by: Ping Li, et al.
Published: (2024-03-01) -
The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
by: Pedro Besada, et al.
Published: (2021-12-01) -
Genotype–Phenotype Correlation in a New Fabry-Disease-Causing Mutation
by: Agnė Čerkauskaitė, et al.
Published: (2019-05-01) -
Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations
by: Raafiah Izhar, et al.
Published: (2023-12-01) -
Genomic analysis of Brazilian patients with Fabry disease
by: F.S. Pereira, et al.
Published: (2007-12-01)